An 8-week Double-blind, Multicenter, Randomized, 6-arm, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren and Amlodipine) in Patients With Essential Hypertension.
Phase of Trial: Phase III
Latest Information Update: 24 Aug 2016
At a glance
- Drugs Aliskiren/amlodipine (Primary) ; Aliskiren; Amlodipine
- Indications Essential hypertension
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Novartis
- 12 Jun 2012 Actual patient number changed from 944 to 1342 as reported by ClincialTrials.gov (Parent trial: NCT01237223).
- 25 May 2011 Actual end date (May 2011) added as reported by ClinicalTrials.gov (NCT01237223).
- 25 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov (NCT01237223).